Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Prostate Cancer ; 2014: 490315, 2014.
Article in English | MEDLINE | ID: mdl-25548680

ABSTRACT

Objectives. Long-term assessment of the efficacy and tolerability of subcutaneous abdominal histrelin acetate implants that have been inserted for more than two years. Materials and Methods. Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant. Results. Following insertion of the first implant, 92.1% and 91.8% of patients had a serum testosterone level of ≤30 ng/dL at 24 and 48 weeks, respectively. Serum testosterone levels remained at <30 ng/dL for 96% of patients at two years and for 100% of patients at 3, 4, and 5 years. The testosterone levels remained significantly less than baseline (P < 0.05). Six patients (5.3%) had androgen-independent progression when followed up on the long term, increasing the mean serum PSA at 3, 4, and 5 years to 35.0 µg/L (n = 22), 30.7 µg/L (n = 13), and 132.9 µg/L (n = 8), respectively. The mean serum PSA was significantly greater than baseline during these years (P < 0.05). Eight patients (7.1%) experienced minor, but not serious, adverse events from the histrelin acetate. Conclusion. Subcutaneous abdominal histrelin acetate implants are an effective long-term and well-tolerated administration method for treating patients with advanced prostate cancer.

2.
Int J Urol ; 19(11): 1031-5, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22774774

ABSTRACT

The Combination of Avodart and Tamsulosin study was a 4-year, randomized, double-blind study of the efficacy and safety of dutasteride and tamsulosin, alone or in combination, in men with moderate-to-severe benign prostatic hyperplasia. In this post-hoc investigation, we analyzed primary and secondary end-points from the Combination of Avodart and Tamsulosin study in Asian (n = 325) and Caucasian men (n = 4259). The incidence of acute urinary retention or benign prostatic hyperplasia-related surgery did not differ significantly between treatment groups in the Asian subpopulation. In Caucasian men, the incidence of acute urinary retention/benign prostatic hyperplasia-related surgery was significantly lower in the combination therapy group compared with the tamsulosin monotherapy group (P < 0.001), but not compared with dutasteride monotherapy. Combination therapy significantly increased the time to benign prostatic hyperplasia clinical progression and resulted in improved International Prostate Symptom Score, maximum urinary flow rate, quality of life, and reduced prostate volume in Asian and Caucasian men who received combination therapy compared with tamsulosin monotherapy. Combination therapy also significantly improved (P < 0.05) time to benign prostatic hyperplasia clinical progression, International Prostate Symptom Score, maximum urinary flow rate and quality of life versus dutasteride in the Caucasian subpopulation. The adverse-event profile was comparable between subpopulations. In conclusion, Asian and Caucasian men respond similarly to these treatments, despite apparent racial differences in 5α-reductase activity.


Subject(s)
5-alpha Reductase Inhibitors/therapeutic use , Adrenergic alpha-1 Receptor Antagonists/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Azasteroids/therapeutic use , Prostatic Hyperplasia/drug therapy , Sulfonamides/therapeutic use , 5-alpha Reductase Inhibitors/administration & dosage , 5-alpha Reductase Inhibitors/adverse effects , Adrenergic alpha-1 Receptor Antagonists/administration & dosage , Adrenergic alpha-1 Receptor Antagonists/adverse effects , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Asian People , Azasteroids/administration & dosage , Azasteroids/adverse effects , Double-Blind Method , Dutasteride , Humans , Male , Middle Aged , Sulfonamides/administration & dosage , Sulfonamides/adverse effects , Tamsulosin , Treatment Outcome , White People
3.
Neurourol Urodyn ; 30(7): 1214-9, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21462240

ABSTRACT

AIMS: Once-daily extended-release (XR) trospium chloride has been evaluated for the treatment of overactive bladder syndrome (OAB) in two 12-week randomized, double-blind, placebo-controlled studies. This pooled analysis of the 9-month open-label extensions to these studies evaluated the long-term efficacy and tolerability of trospium XR. METHODS: Following double-blind treatment, subjects with OAB could enter the open-label period, during which they received trospium 60 mg XR once daily for 36 weeks. The primary efficacy variables were changes from baseline in the number of toilet voids and urgency urinary incontinence (UUI) episodes per day at Week 48. Adverse events (AEs) were also recorded. RESULTS: Of the 1,027 subjects who completed double-blind treatment, 944 (92%) continued into the open-label period (placebo-to-trospium, N = 483; trospium-to-trospium, N = 461); 332 (68.7%) and 335 (72.7%), respectively, completed the open-label period. At Week 48, the mean change from baseline in the number of toilet voids/day was -3.21 in the placebo-to-trospium group and -3.35 in the trospium-to-trospium group, and the median change from baseline in the number of UUI episodes/day was -2.33 in both groups. Efficacy was maintained relative to Week 12 in trospium-to-trospium subjects, while improvement was seen following trospium initiation in placebo-to-trospium subjects. Improvement from baseline was also observed on secondary efficacy parameters at Week 48. Trospium was well tolerated; dry mouth and constipation were the most common class treatment-emergent AEs. Central nervous system AEs were rare and did not increase with long-term treatment. CONCLUSIONS: Long-term treatment of OAB with once-daily trospium 60 mg XR is effective and well tolerated.


Subject(s)
Muscarinic Antagonists/administration & dosage , Nortropanes/administration & dosage , Urinary Bladder, Overactive/drug therapy , Urinary Bladder/drug effects , Urinary Incontinence, Urge/drug therapy , Aged , Benzilates , Delayed-Action Preparations , Double-Blind Method , Drug Administration Schedule , Evidence-Based Medicine , Female , Humans , Male , Middle Aged , Muscarinic Antagonists/adverse effects , Nortropanes/adverse effects , Randomized Controlled Trials as Topic , Time Factors , Treatment Outcome , Urinary Bladder/innervation , Urinary Bladder, Overactive/diagnosis , Urinary Bladder, Overactive/physiopathology , Urinary Incontinence, Urge/diagnosis , Urinary Incontinence, Urge/physiopathology , Urodynamics/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...